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A B S T R A C T
Background: Crimean-Congo hemorrhagic fever (CCHF) is acute viral infection and a major emerging
infectious diseases threat, affecting a large geographical area. There is no proven antiviral therapy and it
has a case fatality rate of 4–30%. The natural history of disease and outcomes of CCHF in pregnant women
is poorly understood.
Objectives: To systematically review the characteristics of CCHF in pregnancy, and report a case series of
8 CCHF cases in pregnant women from Russia, Kazakhstan and Turkey.
Methods: A systematic review was performed following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement protocol. PubMed, SCOPUS, Science Citation Index (SCI)
were searched for reports published between January 1960 and June 2016. Two independent reviewers
selected and reviewed studies and extracted data.
Results: Thirty-four cases of CCHF in pregnancy were identiﬁed, and combined with the case series data,
42 cases were analyzed. The majority of cases originated in Turkey (14), Iran (10) and Russia (6). There
was a maternal mortality of 14/41(34%) and fetal/neonatal mortality of in 24/41 cases (58.5%).
Hemorrhage was associated with maternal (p = 0.009) and fetal/neonatal death (p < 0.0001). There was
nosocomial transmission to 38 cases from 6/37 index pregnant cases.
Conclusion: Cases of CCHF in pregnancy are rare, but associated with high rates of maternal and fetal
mortality, and nosocomial transmission.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Crimean-Congo hemorrhagic fever (CCHF) is an acute tick-
borne viral infection and a major emerging infectious diseases
threat. It affects a wide geographical area, centered in Eurasia
including Turkey, Russia and Kazakhstan but is under-reported
and diagnosis is often delayed. Fever, thrombocytopenia and* Corresponding author at: Liverpool School of Tropical Medicine, Liverpool,
United Kingdom. Phone: +447919912308.
E-mail address: tomﬂetcher@doctors.org.uk (T.E. Fletcher).
http://dx.doi.org/10.1016/j.ijid.2017.02.019
1201-9712/© 2017 The Authors. Published by Elsevier Ltd on behalf of International So
(http://creativecommons.org/licenses/by/4.0/).hemorrhage are the characteristic clinical features, with
supportive care forming the mainstay of treatment protocols,
although ribavirin is utilized by some centers. Provision of
blood product support and access to critical care interventions
can improve outcomes, with reported case fatality rates (CFR)
being 4–20%.1
The majority of cases of CCHF report a history of tick bite, but
healthcare related transmission of CCHF is well reported, and
occurs in both high and low-resource settings. Failure to
recognize CCHF and as a result implement appropriate infection,
prevention and control procedures results in signiﬁcant
nosocomial risk, especially in the context of critical careciety for Infectious Diseases. This is an open access article under the CC BY license
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Figure 1. Flowchart of literature search.
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strated that needle stick injuries are the most frequent cause of
high risk exposures, followed by ‘splash’ exposures to mucous
membranes and highlighted a potential beneﬁt of ribavirin post-
exposure prophylaxis.5
Although the immune system changes in pregnancy are not
completely understood, pregnant woman may be more likely to
acquire certain infectious diseases such as toxoplasmosis, and be
more severely affected by others such as inﬂuenza and varicella.6
Viral hemorrhagic fevers such as Ebola virus disease and Lassa
Fever are more severe in pregnancy,7,8 and frequently result in
spontaneous abortion with additional nosocomial risk. Although
clinical and epidemiological CCHF data are increasingly reported,
few data exist on CCHF in pregnancy.9–11 The mortality of CCHF
disease in pregnant women appears to be higher than in the
general population (up to 33%),10 and the severe course of CCHF in
pregnant women may also increase risk of nosocomial infection in
health care settings.2
In this study we aimed to systematically review the character-
istics of CCHF cases in pregnancy, and to report an additional case
series of 8 CCHF cases in pregnant women from Russia, Kazakhstan
and Turkey.
Material and methods
We planned and reported this systematic review in accordance
with guidelines for performing and reporting systematic reviews
and meta-analyses (PRISMA, Preferred Reporting Items for
Systematic Reviews and Meta-Analyses). We searched PubMED,
Science Citation Index (SCI) and Scopus databases for English and
foreign language studies published between January 1960 and
June 2016. The keyword ‘Crimean Congo H(a)hemorrhagic Fever”
was utilised then combined with “pregnancy”; ‘pregnant’ and
‘vertical’. We also searched reference sections; Google scholar and
reviews for other studies. Statistical analyses were performed
with the use of IBM SPSS Statistics for Windows; Version 24.0.
Armonk; NY: IBM Corp.Study Selection
Two reviewers (HL & IB) independently screened the titles and
abstracts of all studies that were identiﬁed through database
searches. Inclusion criteria were (1): report of a case of laboratory
conﬁrmed Crimean-Congo Hemorrhagic fever OR report of a
clinical case with a direct epidemiological link to a laboratory
conﬁrmed case of Crimean-Congo hemorrhagic fever and (2);
pregnancy. Full-text copies of potentially relevant studies were
retrieved and reviewed independently (TF & IB), extracting data
from each study meeting inclusion criteria. Standardised data was
extracted from each case when available including date, age,
gestation, laboratory diagnosis, outcome of mother and foetus,
hemorrhagic manifestations and secondary cases.
Results
The initial search results identiﬁed the following number of
records: Scopus 3275; PubMED 1205; and SCI 1042. After removal
of duplicates 3507 records were combined with secondary search
terms (Pregnancy: 101, pregnant:114, vertical:109,). An additional
search by Google scholar identiﬁed 2 further reports. 20 full text
articles were then retrieved, with the total number of 34 CCHF
cases identiﬁed in pregnancy in 15 articles (Figure 1). An additional
8 cases were added from this case series from Russia (5 cases),
Kazakhstan (2 cases) and Turkey (1 case), resulting in total of
42 cases of CCHF in pregnancy (Table 1).
The ﬁrst report was from a case in 1979 and the last case
occurred in 2016, with cases from Turkey (14 cases), Iran (10 cases),
Russia (6 cases), former Yugoslavia (4 cases), Iraq (3 cases),
Kazakhstan (2 cases), Mauritania (2 cases) and Bulgaria (1 case).
Gestation was reported in 29 cases, with 11 cases occurring in the
ﬁrst 20 weeks of pregnancy and 18 cases occurring in the second
20 weeks of pregnancy.
Maternal and fetal/neonatal outcome was reported in 41 cases,
with 14/41 cases (34%) reporting maternal death, and foetal/
neonatal death occurring in 24/41 cases (58.5%). In the ﬁrst
Table 1
Characteristic of pregnant CCHF cases.
Authors Country Year (s) No.
cases
Diagnosis Age Gestation Maternal
outcome
Hemorr-
hage
Fetal/Neo-natal
outcome
Ribavirin Secondary
cases
Al-Tikriti SK
et al.31
Iraq 1979 3 Viral culture/
clinical
ND ND Died Yes Died No No
ND ND Died Yes Died No No
ND ND Survived Yes Died No No
Baljosevic. S
et al.32
Former
Yugoslavia
1986–
1995
4 UK 29 32/40 Died Yes Died ND ND
30 24/40 Died Yes Died ND ND
39 38/40 Died Yes Died ND ND
24 11/40 Survived Yes Died ND ND
Sharif-Mood B
et al.11
Iran 2000–
2005
6 PCR/Serology 19–
38
ND Survived Yes Died Yes No
PCR/Serology ND Survived Yes Died Yes No
PCR/Serology ND Survived Yes Died Yes No
PCR/Serology ND Survived Yes Survived Yes No
PCR/Serology ND Survived Yes Survived Yes No
PCR/Serology 16/40 Died Yes Died Yes No
Nabeth P et al.19 Mauritania 2003 2 Clinical 30 ND Died Yes Died No Yes (19)
Clinical ND ND ND ND ND No ND
Ergonul O et al.9 Turkey 2003–
2008
3 Serology 40 38/40 Survived Yes Died Yes No
PCR 20 19/40 Survived Yes Died No No
PCR/Serology 28 28/40 Died Yes Died No No
Gozel MG et al.10 Turkey 2007–
2011
5 PCR/Serology 35 8/40 Survived Yes Died No No
PCR/Serology 30 18/40 Survived No Survived No No
PCR 41 20/40 Survived No Survived No No
PCR/Serology 19 21/40 Survived No Survived No No
PCR/Serology 27 33/40 Survived No Survived No No
Oskooei HO
et al.33
Iran 2008 1 Serology UK UK Survived No Survived Yes No
Dizbay M et al.34 Turkey 2009 1 PCR/Serology 22 36/40 Survived Yes Survived Yes No
Naderi HR et al.18 Iran 2009 2 (PCR +ve secondary
cases)
UK ND Died Yes Died No Yes (1)
31 ND Died Yes Died No Yes (4)
Mumdchiev-a H
et al.35
Bulgaria 2009 1 PCR/Serology UK 26/40 Survived Yes Survived UK No
Aydemir O et al.36 Turkey 2010 1 PCR 29 30/40 Survived No Survived No No
Pshenichnya N
et al.2
Russia 2011 1 PCR 23 22/40 Died Yes Died No Yes (8)
Mardani M et al.37 Iran 2011 1 PCR/Serology 24 16/40 Survived Yes Survived Yes No
Duygu F et al.38 Turkey 2011 2 PCR 25 17/40 Survived Yes Survived No No
PCR 22 20/40 Survived No Survived No No
Ünlüsoy-Aksu A
et al.39
Turkey 2014 1 PCR 23 36/40 Survived Yes Survived Yes No
Pschenichnaya N
et al.
Russia 2002 8 PCR/Serology 20 16/40 Survived No Survived No No
Russia 2003 Serology 19 38/40 Survived No Survived Yes No
Russia 2004 PCR 17 30/40 Died Yes Died No No
Russia 2005 Serology 24 17/40 Survived Yes Died No No
Kazakhstan 2009 Immunohist 23 40/40 Died Yes Died No Yes (5)
Kazakhstan 2010 Immunohist 21 34/40 Died Yes Died No Yes (1)
Russia 2011 PCR 17 18/40 Survived No Survived Yes No
Turkey 2016 PCR 20 04/40 Survived Yes Died No No
ND – Not determined. PCR – polymerase chain reaction, Immunohist – Immunohistochemistry.
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fetal deaths, and in weeks 20–40 of pregnancy there were 8/
18 maternal deaths and 9/18 fetal/neonatal deaths. There was no
statistically signiﬁcant difference between maternal deaths in the
1st 20 weeks of pregnancy compared to weeks 20–40 (p = 0.096–
Fisher’s exact test, two-tailed). There was no haemorrhage in 10/
41 cases, with maternal and fetal survival occurring in all 10 cases.
When maternal haemorrhage was reported (vaginal or other sites),
there were 14/31 maternal deaths and 24/31 fetal/neonatal deaths.
When compared to the non-haemorrhage group (0/10) differences
in outcome were statistically signiﬁcant (p = 0.009, and
p < 0.0001 respectively, Fisher’s exact test, two-tailed). Nosocomi-
al transmission from pregnant CCHF cases was reported in 6/
37 cases, resulting in additional 38 cases.CCHF case series
Case 1 (Stavropol region, Russia, 2002)
A 20-year-old pregnant woman (16-weeks gestation) was
admitted to the infectious diseases hospital on the 3rd day of
disease with fever (38,5 C), headache, loss of appetite and a
petechial rash on her lower limbs. She was an agriculture worker
and had contact with animals, but denied any history of tick bite.
Initial laboratory tests were: Hb 87 g/l, RBC 3.2  1012/L, WBC
3.4 109/L, PLT 112  109/L, APTT 46 secs. CCHF was suspected and
conﬁrmed by PCR on the 4th day of disease, with a positive ELISA
result in the second week. Empirical antibiotics and supportive
treatment were given (no Ribavirin) and 2 days later her condition
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(WBC 7.5 109/L, PLT 144 109/L) and she was discharged after a
16-day admission. At 38 weeks of pregnancy she gave birth to a
healthy child.
Case 2 (Stavropol region, Russia, 2003)
A 19-year-old pregnant woman (38-weeks gestation) was
admitted to the infectious diseases hospital with a one-day history
of fever (up to 39

C), headache, and myalgia. She lived in a rural
area and several days previously reported removing ticks from her
cow. CCHF was suspected and laboratory tests at admission were:
Hb 95 g/L, RBC 3.2  1012/L, WBC 3.8  109/L, PLT 132  109/L and
APTT 46 secs. Ribavirin, empiric antimicrobials and supportive
treatment were commenced and 2–3 days later her condition
improved, and her fever settled. Her laboratory tests improved by
day 8 (HB 110 g/l, RBC 3.8  1012/L, WBC 4.2  109/L, PLT 153  109/
L, APTT 44 secs) and she had no hemorrhagic manifestations. CCHF
was conﬁrmed by ELISA and on day 11 she was transferred to a
maternity unit, where 3 days later she gave birth to a healthy baby.
Case 3 (Izobilnensky district, Stavropol region, Russia, 2004)
A 17-year-old pregnant woman (30-weeks gestation) was
admitted to the gynecology department with a 2-day history of
high fever (>39 C) and back pain. She lived in rural area (with
suspected tick contact) and laboratory tests were: HB 102 g/L, RBC
3.5 1012/L, WBC 5.6  109/L, PLT 153 109/L, ESR 20 mm/h, APTT
43 secs, leukocyturia and proteinuria (2 g/l). Acute pyelonephritis
was the initial diagnosis and anti-bacterial and supportive
treatment was started, but did not result in any signiﬁcant
improvement in her clinical condition.
On the 4th day of illness a hemorrhagic rash appeared on her
lower limbs, with ecchymosis developing on the skin of her chest
and abdomen. She became hypotensive (90/60 mmHg), with
increased respiratory rate (24/min), and worsening of her
laboratory parameters (Hb72 g/L, RBC 2.1 1012/L, WBC
5.6  109/L, Plt 32  109/L and APTT 48 secs). CCHF was suspected
and conﬁrmed by PCR (CCHF IgM negative) and she was
transferred to the infectious diseases department. On the 5th
day of illness there was onset of premature labour and a stillborn
baby was delivered. This was further complicated by post-partum
and gastrointestinal tract hemorrhage, development of acute
respiratory distress syndrome and the patient died on the 6th day
of disease. Ribavirin was not administered to the patient.
Case 4 (Malgobeksky district, Republic of Ingushetia, Russia, 2005)
A 24-year-old pregnant physician (17-weeks gestation) pre-
sented with a 4-day history of fever (39 C), thirst, abdominal pain,
vomiting and cough. She had had previous occupational exposure
during phlebotomy and processing of blood samples from a 75-
year old patient (index patient), who died of massive gastrointes-
tinal hemorrhage.12 Two daughters, who provided care at home
also died. The pregnant physician was initially hospitalized in the
gynecology department and on the 10th day of illness was
transferred to a regional infectious department with suspected
viral hepatitis. At this stage she had developed jaundice,
ecchymosis at injection sites, a hemorrhagic rash, hepatomegaly,
splenomegaly and a right-sided pneumonia. She was managed
with antimicrobial therapy and supportive treatment, and was
transferred to the National Scientiﬁc Research Institute of
obstetrics and pediatrics in Moscow (NSRIOP) on the 12th day
of disease. She remained febrile, and became critically unwell with
respiratory distress and was transferred to the Intensive care unit(ICU) (Hb 60 g/L, PLT 400  109/L, WBC 10.7  109/L, ESR 40 mm/h,
APTT 58 secs).
She was subsequently transferred to the ICU of National
Institute of hematology in a comatose condition with a suspected
hematological disease, but following infectious diseases review,
CCHF was suspected and she was transferred to the ICU of
infectious diseases hospital on the 16 day of disease. Progressive
pneumonia, myocarditis, hepatic insufﬁciency, antenatal fetal
death, and a disseminated intravascular coagulation (DIC)-
syndrome were diagnosed at this point. A caesarean section
was performed on the 18th day of illness and a dead fetus without
hemorrhagic manifestations was extracted. The patient remained
on a ventilator for several weeks, and after her condition
improved she was extubated and then discharged from hospital
2 months later. CCHF RT-PCR from samples taken on day 15 were
negative, but the diagnosis conﬁrmed by ELISA with positive
CCHF IgM and increasing titers of IgG. The patient was not treated
with ribavirin.
Case 5 (Turkestan city, Southern-Kazakhstan region, Kazakhstan,
2009)
A 23-year-old woman was re-admitted to a maternity unit with
her 7-day-old newborn 3 days after discharge, with high fever and
vaginal bleeding. Post-partum endometritis with secondary post-
partum hemorrhage was suspected, and emergency hysterectomy
was performed for severe blood loss. Intra-abdominal hemorrhage
continued and despite two further laparotomies she died. A few
days later her baby also died. CCHF was diagnosed in the woman
based on post-mortem results, and it was suspected that she
acquired this in the last week of pregnancy. Two clinicians who
performed surgical interventions on patient, and the pediatrician
who managed the newborn (without direct contact with the
mother) also contracted CCHF and died. Diagnosis was conﬁrmed
was conﬁrmed by immuno-histochemical analysis of samples at
post-mortem. Two more HCWs who cared for woman also
developed CCHF, but survived.
Case 6 (Turkestan city, Southern-Kazakhstan region, Kazakhstan,
2010)
A 21-year-old pregnant woman (34-weeks gestation) was
admitted to the maternity hospital with a 4-day history high fever
(>39 C), dizziness, thirst and anorexia. She also complained of left
sided abdominal/ﬂank pain, was hypotensive (BP 90/60) and no
fetal heart beat was found. She lived in rural area with animal
contact, but denied a history of tick bite. The initial diagnosis was
acute pyelonephritis and antenatal death, but CCHF was then
suspected due to the thrombocytopenia (PLT 23  109/L) in her
initial blood tests. Hematomas were also observed at injection
sites, and she then deteriorated rapidly with loss of consciousness,
upper gastrointestinal hemorrhage, and uterine bleeding, dying
7 hours after admission. CCHF viral antigen was subsequently
detected by immuno-histochemical staining of post-mortem
tissues samples. One health care worker (nurse) who managed
the patient wearing only gloves as personal protective equipment,
later developed conﬁrmed CCHF.
Case 7 (Rostov-on-Don, Russia, 2011)
A 17-year-old pregnant woman (18-weeks gestation) was
admitted to infectious diseases hospital with a 2-day history of
fever (up to 39 C), headache, and myalgia. Her initial laboratory
tests were: Hb 90 g/L, RBC 3.4 1012/L, WBC 3.2  109/L, PLT
162  109/L and APTT 44 secs. She had a history of tick bite 7 days
previously, CCHF was suspected and conﬁrmed by RT-PCR on day
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were started and 2–3 days later her condition improved, tempera-
ture decreased and laboratory results improved (WBC 8,7  109/L,
PLT 232  109/L and APTT 43 secs). Hemorrhage was not evident
during her disease course and she was discharged from hospital
after 10 days and at term gave birth to a healthy child.
Case 8 (Tokat, Turkey, 2016)
A 20-year-old woman in early pregnancy (estimated 4-weeks
gestation) was admitted to Tokat State Hospital 1 day after a tick
bite with a history of fever, sore throat, back pain anorexia, nausea
and vomiting. Laboratory tests showed: WBC 1.75 109/L, Plt
46  109/L, APTT 53 secs, PT 17.2, AST 233 IU/L and ALT 98 IU/L.
CCHF was suspected and RT-PCR positive from day 2 of illness. On
day 3 of illness she developed vaginal bleeding and was referred
to Tokat University Hospital with progressive thrombocytopenia
(WBC 1.65 109/L, Plt 23 109/L, APTT 53 sec, PT 17.2, AST 270 IU/
L, ALT 127 IU/L). She received 2 units of fresh frozen plasma and
1 unit of platelets and ribavirin was not given. Pelvic ultrasound
showed a thickened endometrium with minimal cervical
bleeding on examination. Her Beta HCG progressively reduced
(2500IU  143IU) and a complete spontaneous abortion was
conﬁrmed. She clinically improved and was discharged 9 days
after admission.
Discussion
Crimean-Congo hemorrhagic fever has been designated a
priority global diseases threat by the World Health Organiza-
tion.12 Its pathophysiology remains incompletely understood,
particularly in vulnerable groups, despite recent increases in
research efforts.13 Other viral hemorrhagic fevers, such as Ebola
virus and Lassa fever, are thought to be more severe in pregnancy,
resulting in higher maternal mortality rates. Pregnant patients
with VHF also present additional infection, prevention and
control challenges, due to the interventions required for obstetric
complications and potential viral persistence in the fetus/
products of conception. Limited data exists describing the course
of CCHF in pregnancy, and we aimed to improve knowledge in this
area through a systematic review of published cases and multi-
national case series.
The most complete data set previously reported was by Gozel
et al. in 2014 who published a case series of 5 pregnant women
with CCHF and summary data on 21 other reported cases.10 Our
systematic review identiﬁed an additional 7 reports (10 cases), that
combined with our large additional case series provided a total
42 cases of CCHF in pregnancy for analysis. CCHF appears to be
associated with more severe disease in pregnancy, with 14/41 cases
(34%) resulting in maternal death. This is higher than overall case
fatality rates in Turkey (5%),14 Russia (4%)15 and Kazakhstan
(14.8%),16 but may reﬂect reporting bias, and national sub-group
analysis of pregnant cases shows rates to be more comparable
(pregnant cases from Turkey 1/14, 9.3%). There is however, a high
rate of fetal/neonatal loss occurring in 24/41 cases (58.5%). In the
majority of cases this is through spontaneous abortion early in
pregnancy or associated with maternal death. Still birth appears to
be rare as does neonatal death.
The stage of the pregnancy when CCHF occurs may also
inﬂuence maternal mortality, with 8/18 mothers dying in the
second half of pregnancy (>20 weeks) compared with 1/11 dying in
the ﬁrst half of pregnancy (<20 weeks), although this was not
statistically signiﬁcant (p = 0.096). In our cases series 3/8 cases
resulted in maternal death occurring at 34, 38 and 40-weeks
gestation. However, as we have highlighted in cases 4 & 8, with
appropriate critical care interventions and blood product support,positive outcomes are possible in the context of severe CCHF in
pregnancy. This was also demonstrated by Ergonul et al.,9 who
reported a case of severe CCHF in late pregnancy that survived, but
required 22 units of fresh frozen plasma, 54 units of platelets and
repeat surgical intervention for ongoing uterine hemorrhage after
caesarian section.
Due to the risk of nosocomial transmission, surgical interventions
in pregnant women with CCHF require careful infection prevention
and control planning and risk assessment. Although caesarian
section was performed in 2 cases that we have summarized, with no
secondary nosocomial transmission, the patients had tested RT-PCR
negative in blood prior to the operations. The PCR status of the fetus
and amniotic ﬂuid at the time surgery was not known, but in the case
reported by Ergonul et al., the neonate subsequently tested CCHF RT-
PCR positive and died.9 However, surgery was undertaken for post-
partum hemorrhage in case 5 resulting in nosocomial transmission
to 2 surgeons, and the neonate also transmitted CCHF to a further
3 healthcare workers. The additional nosocomial risk of pregnancyin
other VHFs is not well understood, and during the Ebola outbreak in
West Africa there were signiﬁcant limitations on pregnant women’s
access to obstetric care. However, complicated cases were managed
successfully,17 and caesarian sections were undertaken by one group
in Monroviawith noassociatednosocomial transmission(Dr J Brown
personal communication).
Six of the 42 pregnant CCHF cases we identiﬁed did result in
subsequent cases of CCHF as a result of nosocomial transmission.
Naderi et al.,18 reported a nosocomial outbreak where a pregnant
woman was an index case that infected another pregnant woman
whilst sharing a room, who then infected another 4 healthcare
workers. Nabeth et al.,19 conducted an investigation into a large
nosocomial outbreak in Mauritania in 2003, identifying a 30-year
old pregnant woman with severe CCHF as the index case. She
directly infected a total of 15 healthcare workers, patients and
visitors in the ward and emergency room setting with six fatal
cases. A more recent report from Russia2 also highlighted the
nosocomial risk of critical care interventions, particularly aerosol
generating procedures that resulted in 8 healthcare worker
infections, from a 23-year old pregnant woman. In all these cases
CCHF was not initially suspected. The initial presentation of CCHF
is non-speciﬁc, and a lack of healthcare worker awareness, that
occurs in both endemic settings and in exported cases can result
in delayed diagnosis of CCHF. This can delay initiation of
supportive treatment for CCHF and also the required infection
prevention and control measures. In our series there was a delay
in recognition of CCHF in pregnant women in 4/8 cases (cases 3, 4,
5 & 6), all associated with severe/fatal disease and fetal death.
There is currently no speciﬁc antiviral therapy for CCHF, and the
beneﬁt of ribavirin treatment is controversial with mixed results
mainly generated from retrospective studies.20 Its use is contra-
indicated in pregnancy (FDA Pregnancy Category X) due to
signiﬁcant teratogenecity being demonstrated in all animal species
in which adequate studies have been performed.21 However, in
ribavirin’s submission for inclusion in the WHO model list of
essential medicines, its risk/beneﬁt in pregnancy, in the context of
the high mortality in VHF was re-considered.22 This was though
predominantly based on its clearer evidence base in the treatment
of Lassa fever and Argentinian Hemorrhagic fever23 and early
reports of beneﬁt in CCHF.
Ribavirin may have greater effect in late stage pregnancy where
mortality appears to be higher, risk of teratogenicity lower, and we
believe its use may be justiﬁed in this scenario. In our combined
data when treatment and outcome was known, 5/13 pregnant
women died who received ribavirin, compared to 15/23 who died
who did not receive ribavirin. The difference is not statistically
signiﬁcant and caution must be applied to any interpretation and
conclusions on interventions from this retrospective analysis.
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survival beneﬁt in CCHF animal models,24 is also contraindicated in
pregnancy due to teratogenicity and embryogenicity25 Pregnancy
was also an exclusion criteria for its use in the JIKI Ebola clinical
trial.26 Limited data exists on the risk of transmission through
breast feeding in CCHF, with only 2 cases reported.27 In both cases
RT-PCR was positive in the mother’s blood and negative in
breastmilk, and the babies did not go on to develop CCHF. In our
units breastfeeding is not recommended during the acute illness
phase of CCHF, due to established risks of CCHF transmission to the
baby. Samples of breastmilk would then be sent for RT-PCR as the
patient recovered.
There is currently no CCHF vaccine that is licensed by the
European Medicines Agency or US Food and Drug Administration.
An inactivated mouse brain vaccine was developed by the former
Soviet Union in the 1970s, and is still in use in Bulgaria. However, it
has failed to show high neutralizing antibody levels,28 and lacks
controlled data demonstrating protective efﬁcacy. A number of
promising CCHF vaccine candidates are under development,29,30
and will soon proceed to phase 1 clinical trials. Pregnant women in
endemic areas should be considered a high-risk CCHF group that
requires particular consideration with respect to vaccine safety
evaluation and during future roll-out strategies.
Limitations to the systematic review are the incomplete
information provided in some case descriptions, particularly on
gestation of pregnancy. The total numbers identiﬁed also probably
represent a signiﬁcant underestimate due to incomplete reporting
of cases from endemic regions and the likelihood of undiagnosed
mild CCHF pregnant cases. Due to its non-speciﬁc clinical
presentation CCHF in pregnancy can be difﬁcult to distinguish
from other causes of undifferentiated febrile illness. This is
exacerbated by a lack of laboratory capacity in endemic regions
combined with a lack of awareness of CCHF by clinicians.
Hemorrhagic signs start around the fourth day of illness and it
is often only at this stage that CCHF ﬁrst considered, or as we have
reported when there are secondary nosocomial cases.
Conclusions
The number of reported cases of CCHF in pregnant women is
low, but this is an underestimate and the geographical range of
CCHF is increasing, including within Europe. Clinicians must
maintain a high index of suspicion and undertake risk assessments
for CCHF in pregnant women with a fever, who reside in or who
have a history of travel to CCHF endemic areas. Early recognition
allows appropriate infection prevention and control precautions to
be put in place, reducing the demonstrated risk of nosocomial
transmission. In accordance with other viral hemorrhagic fevers,
the mortality of CCHF in pregnant women appears to be increased,
but as we have highlighted supportive care focused on blood
product replacement and access to critical care interventions can
result in positive outcomes in severe disease. Novel therapeutics
are required to improve both maternal and fetal outcomes in CCHF,
and as such pregnant woman should be included in future CCHF
clinical trials whenever possible.
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